




Tazarotene

Revised: June 15, 2024.

CASRN: 118292-40-3



Drug Levels and Effects

Summary of Use during Lactation

Topical tazarotene has not been studied during breastfeeding. Some experts feel it should not be used on a large surface area (perhaps greater than 20% of body surface area) while nursing because of possible absorption.[1] Others recommend that it not be used during breastfeeding because of its suspected mutagenic properties.[2] If tazarotene is used, ensure that the infant's skin does not come into direct contact with the areas of maternal skin that have been treated and the infant does not ingest the product from the mother's skin.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

(Psoriasis) Adalimumab, Certolizumab Pegol, Etanercept, Infliximab, Phototherapy, Tretinoin

References

1. Yaghi M, McMullan P, Truong TM, et al. Safety of dermatologic medications in pregnancy and lactation: An Update - Part II: Lactation. *J Am Acad Dermatol* 2024. PubMed PMID: 38280680.
2. Gottlieb AB, Ryan C, Murase JE. Clinical considerations for the management of psoriasis in women. *Int J Womens Dermatol* 2019;5:141-50. PubMed PMID: 31360745.

Substance Identification

Substance Name

Tazarotene

CAS Registry Number

118292-40-3

Drug Class

Breast Feeding

Lactation

Milk, Human

Dermatologic Agents

Keratolytic Agents